Advertisement
Loading...

Silexion Therapeutics Ltd.

SLXN•NASDAQ
Healthcare
Biotechnology
$0.53
$0.26(96.95%)
U.S. Market opens in 13h 21m

Silexion Therapeutics Ltd. (SLXN) Stock Overview

Explore Silexion Therapeutics Ltd.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap285K
P/E Ratio-0.20
EPS (TTM)$-8.96
ROE-2.98%
Fundamental Analysis

AI Price Forecasts

1 Month$1.70
3 Months$1.90
1 Year Target$2.58

SLXN Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Silexion Therapeutics Ltd. (SLXN) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 39.62, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $2.58.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.20 and a market capitalization of 285K. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
89.29%
5-Day Change
75.59%
1-Month Change
-52.85%
3-Month Change
-67.36%
6-Month Change
-78.33%
Year-to-Date (YTD) Change
-73.48%
1-Year Change
-96.24%
3-Year Change
-99.81%
5-Year Change
-99.81%
All-Time (Max) Change
-99.81%

Contact Information

https://silexion.com
972 2 674 3430
The Goldyne Savad Institute of Gene Therapy, Jerusalem, NaN, 9112001

Company Facts

11 Employees
IPO DateAug 16, 2024
CountryIL
Actively Trading

Frequently Asked Questions